APUS
ApimedsยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APUS
Apimeds Pharmaceuticals Us, Inc.
A clinical stage biopharmaceutical company
Pharmaceutical
05/11/2020
05/09/2025
American Stock Exchange
2
12-31
Common stock
2 East Broad Street 2nd Floor, Hopewell, NJ 08425
--
Apimeds Pharmaceuticals US, Inc., was incorporated in Delaware on May 11, 2020. They are a clinical-stage biopharmaceutical company developing Apitox, an intradermal injection of bee venom toxin. Their focus is primarily on developing innovative therapies to address inflammation and pain management symptoms associated with knee OA.
Company Financials
EPS
APUS has released its 2025 Q2 earnings. EPS was reported at -0.26, versus the expected 0, missing expectations. The chart below visualizes how APUS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
